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2012Introduction
Exudative  ascites,  deﬁned  by  a  protein  rate  higher  25  g/L  and/or  a  serum  albumin  to  ascitic
ﬂuid  albumin  ratio  lower  than  11  g/L  is  usually  seen  in  the  absence  of  portal  hypertension.
Major  causes  are  tumoral,  infectious  and  cardiac.  However,  exudative  ascites  is  possible
in  the  presence  of  portal  hypertension,  mainly  in  suprahepatic  bloc  such  as  hepatic  vein
thrombosis,  but  also  in  intrahepatic  bloc,  since  15%  of  patients  with  cirrhosis  have  exuda-
tive  ascites  after  exclusion  of  other  common  causes  [1,2].  Portal  hypertension  secondary
to  myeloproliferative  disorders  occurs  rarely,  and  is  usually  related  to  portal  or  hepatic
vein  thromboses  whereas  sinusoidal  obstruction  is  less  common.
We  report  herein  the  case  of  a  woman  with  exudative  ascites  related  to  non-
cirrhotic  portal  hypertension  secondary  to  sinusoidal  obstruction  caused  by  extramedullary
hematopoiesis  and  revealing  a  latent  essential  thrombocytemia.
Case report
A  84-year-old  woman,  was  admitted  to  our  department  for  ascites  associated  with
lower  limb  edema.  Anamnesis  revealed  a  recent  loss  of  weight  with  anorexia.  Physical
examination  showed  abdominal  collateral  venous  circulation,  splenomegaly  and  ten-
der  hepatomegaly.  Routine  laboratory  tests  didn’t  show  liver  failure  signs.  Blood  cell
count  disclosed  non-regenerative  hypochromic  microcytic  anemia  (8,9  g/dL)  with  normal
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white  cells  and  platelets  count  (respectively  10,000  and
300,000 elements/mm3).
Serum  ferritin  was  within  normal  limits  as
well as  C-reactive  protein  level  and  erythrocyte
sedimentation  rate  when  correlated  with  the
age.  Level  of  serum  creatinin  was  103  mol/L
and sodium  concentration  was  132  mmol/L.
Biological data  are  detailed  in  Table  1.
Ascites was  exudative  with  a  protein  rate  of  28,5  g/L
and a  serum  albumin  to  ascitic  ﬂuid  albumin  ratio  of  7  g/L
and cell  count  showed  120  white  cells  among  which  60%  of
lymphocytes. Upper  endoscopy  showed  esophageal  varices
grade II  and  hypertensive  gastropathy  and  transthoracic  car-
diac ultrasound  disclosed  pulmonary  arterial  hypertension
up to  56  mm  Hg  without  signs  of  heart  failure.  Thoracoab-
dominal tomodensitometry  revealed  a  dysmorphic  liver  with
hypertrophy of  segment  I  associated  with  a  multinodular
spleen (Fig.  1),  peritoneal  ascites  with  portal  hypertension
signs such  as  collateral  splenorenal  circulation  (Fig.  2).
Portal vein  and  hepatic  veins  thrombosis  were  excluded
with doppler  ultrasonography  and  tomodensitometry.  At
this stage,  the  diagnosis  of  myeloproliferative  syndrome
Table  1  Initial  laboratory  data.
Value  (normal  range)
Hemoglobin  9.5  g/dL
White blood  cell  10,000  mm3
Platelet  count  300,000  mm3
C-reactive  protein  6  mg/L
Erythrocyte sedimentation  rate  51  mm/h
Albumin 38,5  g/L
Alanine aminotransferase  18  UI/L  (<  40)
Aspartate  aminotransferase 23  UI/L  (<  40)
Serum alkaline  phosphatase 129  UI/L  (100—290)
Gamma-glutamyl transpeptidase 25  UI/L  (<  30)
Total bilirubin 13.5 mol/L  (17)
Prothrombine time  11  s  (10—14)
Creatinine 103  mol/L  (45—120)
Sodium 132  mmol/L  (135—145)
Lactate dehydrogenase  400  UI/L  (235—470)
Serum Ferritin  150  ng/mL  (15—200)
Figure 1. Abdominal tomodensitometry showing hypertrophy of
segment  I of the liver and multinodular spleen.
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higure 2. Abdominal tomodensitometry showing splenorenal col-
ateral  circulation.
as  suspected  in  the  presence  of  multinodular  spleen,
ulmonary arterial  hypertension,  portal  hypertension  and
elatively high  rate  of  platelets  in  comparison  with  low
latelet count  expected  in  the  presence  of  enlarged  spleen
nd other  signs  of  portal  hypertension.  Bone  marrow  biopsy
howed medullar  inﬁltration  by  many  megakaryocytes
hich have  a big  size,  a mature  cytoplasm  and  a  hyper
obular nucleus  without  dysplasia.  This  histological  aspect
as consistent  with  essential  thrombocytemia.
The  V617F  Janus  kinase-2  gene  mutation  was  investigated
n peripheral  granulocyte  DNA  and  found  to  be  positive.
However,  as  ascites  was  exudative,  we  decided  to  per-
orm diagnostic  laparoscopy  in  order  to  formally  rule  out
umoral peritoneal  involvement,  especially  peritoneal  car-
inomatosis or  peritoneal  extramedullary  hematopoiesis.
aparoscopy was  normal,  and  peritoneal  and  liver  biopsies
ere performed.  Histological  examination  of  periton-
al samples  didn’t  show  peritoneal  tumoral  invasion
y hematopoietic  or  other  malignant  cells.  Histological
xamination of  liver  samples  disclosed  extra  medullar
ematopoiesis localized  into  hepatic  sinusoid  vessels,
inusoidal ﬁbrosis  and  parenchymal  nodularity  with  thin
ncomplete septa  (Figs.  3  and  4).  The  diagnosis  of  por-
al hypertension  secondary  to  sinusoidal  obstruction  due  to
ssential thrombocythemia  was  the  most  likely.  Treatment
ossibilities were  discussed  by  hemato-oncologist:  antico-
gulation for  prevention  of  thrombotic  events  was  avoided
igure 3. Histological examination of liver biopsy showing
epatic ﬁbrosis with regenerative nodules (hematoxylin eosin).
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Rigure 4. Histological examination of liver biopsy showing
xtramedullar hematopoiesis (among which megakaryocytic cells)
nto  sinusoid hepatic vessels (hematoxylin eosin).
ecause  of  high  risk  of  bleeding  due  to  esophageal  varices,
ytoreductive treatment  was  not  indicated  as  platelet  cells
ount was  less  than  1,500,000/mm3.  Thus,  patient  was
reated symptomatically  by  iterative  paracentesis  as  salt
ree diet  and  diuretics  were  insufﬁcient  for  ascites,  elas-
ic ligature  for  esophageal  varices  and  transfusion  of  packet
ed blood  cells  for  anemia.
iscussion
xudative  ascites  has  multiple  etiologies  among  which  the
ost frequent  are  represented  by  neoplasic,  tuberculosis,
nd cardiac.  Other  etiologies  such  as  suprahepatic  portal
ypertension including  hepatic  vein  thrombosis  or  inferior
ena cava  obstruction  are  less  common  [1].  Intrahepatic
ortal hypertension  usually  induces  transsudative  ascites,
owever, 15%  of  patients  with  cirrhosis  have  exudative
scites in  the  absence  of  other  common  causes  [2].
Essential  thrombocythemia  is  an  acquired  myelopro-
iferative disorder  characterized  by  a  sustained  elevation
f platelet  number  with  a  tendency  for  thrombosis  and
emorrhage [3,4].  The  predominant  clinical  features  are
ersistent thrombocytosis  with  an  increased  platelet  count,
egakaryocytic hyperplasia  and  hemorrhagic  or  thrombotic
endency with  a  predisposition  to  vascular  occlusive  events
5]. Thus,  deep  vein  thrombosis  represents  a  potentially
erious and  eventually  life-threatening  event  related  to
he region  involved  as  it  is  the  case  in  hepatic  or  por-
al vein  thrombosis  [6].  This  myeloproliferative  disorder
eads to  ineffective  hematopoiesis  and  thus  extramedullar
epatopoiesis, predominantly  the  spleen.  However,
xtramedullar hematopoiesis  may  also  occur  in  other  organs
uch as  the  liver  [7].  Physiopathology  of  portal  hypertension
n essential  thrombocythemia  is  still  controversial.  In  the
bsence of  portal  or  hepatic  vein  thromboses  two  main
echanisms have  been  proposed:  the  ﬁrst  theory  concludeshat portal  hypertension  is  due  to  sinusoidal  narrowing
nd intrahepatic  obstruction  caused  by  extramedullar
ematopoiesis  and  inﬁltration  of  the  liver  by  megakaryotic
ells leading  to  increased  intrahepatic  resistance,  while  theR.  Ennaifer  et  al.
econd  theory  advances  that  portal  hypertension  develops
ecause of  increased  portal  blood  ﬂow  through  the  enlarged
pleen [8,9].  In  our  case,  the  ﬁrst  theory  was  the  most  likely,
onﬁrmed by  liver  biopsy.  Nevertheless,  increased  portal
lood ﬂow  through  the  enlarged  spleen  may  also  play  a  role.
onsequences of  these  mechanisms  are,  through  portal
ypertension, the  development  of  ascites,  collateral  circula-
ion and  secondary  hepatic  ischemia  which  results  of  hepatic
ecrosis, and  then  centrolobular  ﬁbrosis  and  regenerative
esions that  determinates  the  histological  aspect  of  classical
irrhosis. In  these  cases,  ﬁbrosis  develops  at  the  expense
f sinusoids  rather  than  hepatocytes  [10,11].  In  this  report,
ttributing exudative  ascites  to  intrahepatic  portal  hyper-
ension was  a  challenge,  since  it  is  usually  transsudative.
he etiology  of  ascites  in  myeloproliferative  disorders  have
een described  elsewhere,  three  majors  sources  have  been
tated: ﬁrst,  portal  hypertension  accompanied  by  ectopic
ematopoiesis in  the  liver  and  the  spleen,  the  second  is  por-
al vein  thrombosis,  the  third  is  ectopic  hematopoiesis  in  the
eritoneum [12].  In  our  case,  we  performed  peritoneal  biop-
ies to  rule  out  the  third  mechanism,  while  portal/hepatic
ein thromboses  have  been  excluded  with  imaging.
In  patients  with  portal  hypertension  secondary  to  latent
yeloproliferative disorder,  positive  diagnosis  is  difﬁcult  to
onﬁrm because  hemodilution,  occult  bleeding,  and  hyper-
plenism may  interfere  with  hematopoiesis  and  mask  the
abitual changes  observed  in  blood  cell  count  [13].  In  our
ase, myeloproliferative  disorder  was  suspected  in  the  pres-
nce of  normal  platelets  count  despite  enlarged  spleen  and
thers signs  of  portal  hypertension.
onclusion
his  report  is  particular  ﬁrst  of  all  because  it  is  unusual  to
elate the  cause  of  exsudative  ascites  to  intrahepatic  por-
al hypertension.  Secondly,  latent  essential  thrombocytemia
evealed by  liver  involvement  is  a  challenging  diagnosis.
inally, in  myeloproloferative  syndromes,  portal  hyperten-
ion is  frequently  due  to  portal  or  hepatic  vein  thrombosis,
hereas sinusoidal  obstruction  is  less  common.
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